Top

Osteoporosis International

Published in:

01-05-2020 | Osteoporosis | Original Article

Modification of the RANKL-RANK-binding site for the immunotherapeutic treatment of osteoporosis

Authors: Y. Ko, G. Lee, B. Kim, M. Park, Y. Jang, W. Lim

Published in: Osteoporosis International | Issue 5/2020

Abstract

Summary

Here, we proposed the use of mutated RANKL as an immunogen for active immunization and to induce anti-cytokine antibodies for osteoporosis treatment.

Introduction

Osteoclasts are responsible for bone resorption in bone-related disorders. Anti-cytokine therapeutic antibodies such as denosumab are effective for the treatment of osteoporosis. However, problems with antibody manufacturing and the immunogenicity caused by multiple antibody doses have led to the use of auto-cytokines as immunogens to induce anti-cytokine antibodies.

Methods

RANKL was point-mutated based on the crystal structure of the complex of RANKL and its receptor RANK.

Results

As a proof of concept, immunization with RANKL produced high levels of specific antibodies and blocked osteoclast development in vitro and inhibited osteoporosis in RANKL-treated or ovariectomized mouse models.

Conclusions

The results demonstrate the successful use of mutated RANKL as an immunogen for the induction of anti-RANKL immune response. This strategy is useful in general anti-cytokine immunotherapy to avoid toxic side effects of osteoporosis treatment.

Everts V, Delaisse JM, Korper W, Jansen DC, Tigchelaar-Gutter W, Saftig P, Beertsen W (2002) The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res 17:77–90CrossRef

Cao X (2011) Targeting osteoclast-osteoblast communication. Nat Med 17:1344–1346CrossRef

Tanaka Y, Nakayamada S, Okada Y (2005) Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy 4:325–328CrossRef

Boyce BF, Xing L (2008) Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473:139–146CrossRef

Burgess TL, Qian Y, Kaufman S et al (1999) The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527–538CrossRef

Lo Iacono N, Blair HC, Poliani PL et al (2012) Osteopetrosis rescue upon RANKL administration to Rankl(-/-) mice: a new therapy for human RANKL-dependent ARO. J Bone Miner Res 27:2501–2510CrossRef

Warren JT, Zou W, Decker CE, Rohatgi N, Nelson CA, Fremont DH, Teitelbaum SL (2015) Correlating RANK ligand/RANK binding kinetics with osteoclast formation and function. J Cell Biochem 116:2476–2483CrossRef

Lam J, Nelson CA, Ross FP, Teitelbaum SL, Fremont DH (2001) Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest 108:971–979CrossRef

Takayanagi H, Kim S, Matsuo K et al (2002) RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 416:744–749CrossRef

10.

Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104:487–501CrossRef

11.

Le Buanec H, Bensussan A, Bagot M, Gallo RC, Zagury D (2012) Active and passive anticytokine immune therapies: current status and development. Adv Immunol 115:187–227CrossRef

12.

Ratsimandresy RA, Rappaport J, Zagury JF (2009) Anti-cytokine therapeutics: history and update. Curr Pharm Des 15:1998–2025CrossRef

13.

Liu C, Zhao Y, He W et al (2015) A RANKL mutant used as an inter-species vaccine for efficient immunotherapy of osteoporosis. Sci Rep 5:14150CrossRef

14.

Kinoshita H, Miyakoshi N, Kashiwagura T, Kasukawa Y, Sugimura Y, Shimada Y (2017) Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis. Mod Rheumatol 27:582–586CrossRef

15.

Kuriakose A, Chirmule N, Nair P (2016) Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications. J Immunol Res 2016:1298473CrossRef

16.

Miyazaki K (2003) Creating random mutagenesis libraries by megaprimer PCR of whole plasmid (MEGAWHOP). Methods Mol Biol 231:23–28PubMed

17.

Bessette PH, Aslund F, Beckwith J, Georgiou G (1999) Efficient folding of proteins with multiple disulfide bonds in the Escherichia coli cytoplasm. Proc Natl Acad Sci U S A 96:13703–13708CrossRef

18.

Sohn H, Ko Y, Park M, Kim B, Kim O, Kim D, Moon YL, Lim W (2016) Cloning and expression of recombinant macrophage-colony stimulating factor-A progressive strategy for economical production. Biotechnol Bioprocess Eng 21:446–452CrossRef

19.

Sohn H, Ko Y, Park M et al (2015) Effects of light-emitting diode irradiation on RANKL-induced osteoclastogenesis. Lasers Surg Med 47:745–755CrossRef

20.

Bargman R, Huang A, Boskey AL, Raggio C, Pleshko N (2010) RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta. Connect Tissue Res 51:123–131CrossRef

21.

Body JJ, Greipp P, Coleman RE et al (2003) A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97:887–892CrossRef

22.

Higgs JT, Jarboe JS, Lee JH, Chanda D, Lee CM, Deivanayagam C, Ponnazhagan S (2015) Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies. Mol Cancer Res 13:819–827CrossRef

23.

Ta HM, Nguyen GT, Jin HM, Choi J, Park H, Kim N, Hwang HY, Kim KK (2010) Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis. Proc Natl Acad Sci U S A 107:20281–20286CrossRef

24.

Krishna M, Nadler SG (2016) Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes. Front Immunol 7:21CrossRef

25.

Semerano L, Assier E, Boissier MC (2012) Anti-cytokine vaccination: a new biotherapy of autoimmunity? Autoimmun Rev 11:785–786CrossRef

26.

Bachmann MF, Dyer MR (2004) Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov 3:81–88CrossRef

27.

Wu T, Li F, Sha X, Li F, Zhang B, Ma W, Liu M, Yang W, Li H, Tao H (2018) A novel recombinant RANKL vaccine prepared by incorporation of an unnatural amino acid into RANKL and its preventive effect in a murine model of collagen-induced arthritis. Int Immunopharmacol 64:326–332CrossRef

28.

Spohn G, Schwarz K, Maurer P, Illges H, Rajasekaran N, Choi Y, Jennings GT, Bachmann MF (2005) Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. J Immunol 175:6211–6218CrossRef

Title: Modification of the RANKL-RANK-binding site for the immunotherapeutic treatment of osteoporosis
Authors: Y. Ko
G. Lee
B. Kim
M. Park
Y. Jang
W. Lim
Publication date: 01-05-2020
Publisher: Springer London
Keywords: Osteoporosis
Osteoporosis
Cytokines
Published in: Osteoporosis International / Issue 5/2020
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-019-05200-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Modification of the RANKL-RANK-binding site for the immunotherapeutic treatment of osteoporosis

Abstract

Summary

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2020

Patient engagement in clinical guidelines development: input from > 1000 members of the Canadian Osteoporosis Patient Network

Osteocrinology

Correction to: Comparison of the clinical effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients

Secondary prevention of fragility fractures in Asia Pacific: an educational initiative

Management of Paget’s disease of bone

Comparison of bone structure and microstructure in the metacarpal heads between patients with psoriatic arthritis and healthy controls: an HR-pQCT study